quinolobactin: a siderophore of Pseudomonas fluorescens, the production of which is repressed by the cognate pyoverdine; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
quinolobactin : A quinolinemonocarboxylic acid that is xanthurenic acid in which the hydroxy group at position 4 is replaced by a methoxy group. It is a siderophore isolated from Pseudomonas fluorescens ATCC 17400. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 46910770 |
| CHEBI ID | 171659 |
| SCHEMBL ID | 1815345 |
| MeSH ID | M0358412 |
| Synonym |
|---|
| CHEBI:171659 |
| 28027-14-7 |
| SCHEMBL1815345 |
| quinolobactin |
| 8-hydroxy-4-methoxyquinoline-2-carboxylic acid |
| DTXSID40677235 |
| 8-hydroxy-4-methoxy-2-quinoline carboxylic acid |
| 2-quinolinecarboxylic acid,8-hydroxy-4-methoxy- |
| 8-hydroxy-4-methoxyquinoline-2-carboxylicacid |
Quinolobactin is a new siderophore produced by a pyoverdine deficient mutant of Pseudomonas fluorescens.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Quinolobactin is a new siderophore produced by a pyoverdine deficient mutant of Pseudomonas fluorescens. " | ( Synthesis and iron-binding properties of quinolobactin, a siderophore from a pyoverdine-deficient Pseudomonas fluorescens. du Dhardemare, AM; Pierre, JL; Serratrice, G, 2004) | 2.03 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Iron is an essential nutrient for almost all bacteria; however, at neutral pH its bioavailability is limited." | ( Siderophores in fluorescent pseudomonads: new tricks from an old dog. Amoutzias, GD; Mossialos, D, 2007) | 0.34 |
| Role | Description |
|---|---|
| siderophore | Any of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron. |
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| monohydroxyquinoline | A hydroxyquinoline carrying a single hydroxy substituent. |
| quinolinemonocarboxylic acid | Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.96) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||